Polpharma launches a platform in Starogard Gdański for the development and manufacturing of RNA-based medicines
Polpharma has launched an investment project for the development and manufacturing of RNA-based medicines, creating in Poland a complete platform covering the entire value chain: from active pharmaceutical ingredient (API) synthesis, through process development and analytics, to the production of the finished medicinal product. The investment—with a total value of PLN 238.7 million—not only reduces Poland’s dependence on imports, but also builds capabilities in one of the most promising fields of modern medicine.
Read more